Almirall Knocked Back By US Woes, Could Affect Other Companies Too

Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.

Compass
Almirall is navigating through difficult waters • Source: Shutterstock

The US is often seen, quite rightly, as a market opportunity for Europe’s pharmaceutical companies, but it can also be an unpredictable market where setbacks can rapidly follow each other in what might seem as an unremitting sequence. Barcelona, Spain-headquartered Almirall SA has just been afflicted by three such setbacks, leading to a lowering in its sales and earnings guidance for 2017.

Almirall’s US business, Aqua, has been adversely impacted by what seems to be the inappropriate use of its patient assistance...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.